PIK3CA and head and neck squamous cell carcinoma: Therefore, here we focused on alterations in the PI3K/AKT and RAS/MAPK pathways as potential biomarkers of resistance to cetuximab among the 115 HNSCC patients treated with cetuximab at the Curie Institute.